FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma By Ogkologos - March 25, 2026 264 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable... January 15, 2025 Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated... June 11, 2025 Adagrasib Demonstrates Clinical Activity Across a Broad Range of Tumour Types... May 3, 2023 Pumpkin Season! October 27, 2020 Load more HOT NEWS Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention... Surgeons Use Tissue From Cancer Survivor’s Love Handles For Rare Type... Man Who Lost His Leg Teaches Martial Arts To Orphans Of... Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of...
